WallStSmart

Aclarion Inc (ACON)vs10X Genomics Inc (TXG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

10X Genomics Inc generates 820114% more annual revenue ($638.78M vs $77,880). ACON leads profitability with a 0.0% profit margin vs -3.5%. ACON earns a higher WallStSmart Score of 29/100 (F).

ACON

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.8
Piotroski: 3/9Altman Z: 2.48

TXG

Avoid

20

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 1.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACON.

TXGUndervalued (+68.1%)

Margin of Safety

+68.1%

Fair Value

$60.02

Current Price

$47.86

$12.16 discount

UndervaluedFair: $60.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACON1 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

TXG1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Areas to Watch

ACON4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.81M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TXG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

Revenue GrowthGrowth
-2.6%2/10

Revenue declined 2.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACON

The strongest argument for ACON centers on Price/Book. Revenue growth of 11.3% demonstrates continued momentum.

Bull Case : TXG

The strongest argument for TXG centers on Debt/Equity.

Bear Case : ACON

The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.

Bear Case : TXG

The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

ACON profiles as a value stock while TXG is a turnaround play — different risk/reward profiles.

TXG carries more volatility with a beta of 2.04 — expect wider price swings.

ACON is growing revenue faster at 11.3% — sustainability is the question.

TXG generates stronger free cash flow (25M), providing more financial flexibility.

Bottom Line

ACON scores higher overall (29/100 vs 20/100) and 11.3% revenue growth. TXG offers better value entry with a 68.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclarion Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Aclarion Inc (ACON) is a pioneering healthcare technology firm dedicated to advancing non-invasive diagnostic solutions for musculoskeletal conditions through cutting-edge imaging and data analytics. By harnessing the power of machine learning, Aclarion empowers healthcare providers with actionable insights that not only improve clinical outcomes but also optimize treatment pathways and reduce costs. Positioned at the forefront of the digital health revolution, the company is well-equipped to meet the rising demand for effective diagnostics, thereby significantly enhancing patient management and care standards in a dynamic healthcare landscape. Aclarion's commitment to improving patient care underscores its vital role in the future of healthcare delivery.

Visit Website →

10X Genomics Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Want to dig deeper into these stocks?